Clinical Trial Update: Monoclonal Antibodies in Detecting Residual Disease in Patients Who Have Been Treated for Non-Hodgkin's Lymphoma [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/Phase 3 trial evaluating monoclonal antibodies for detecting residual disease in patients treated for non-Hodgkin's lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• Monoclonal antibodies (unspecified)

Snippet

Sponsor: Gilead Sciences | Conditions: Lymphoma | Phase 2, Phase 3 | Status: UNKNOWN